Genecast Lung is our NGS-based test for multi-gene mutation detection of non-small cell lung cancer (“NSCLC”).
Genecast Lung detects SNVs, Indels, fusions and CNVs in eleven genes in DNA extracted from FFPE tissue samples and ctDNA from liquid biopsy samples.
It combines genetic testing by sequencing the DNA or ctDNA with analysis against a proprietary database and algorithm, to determine gene mutations and provides the most effective targeted therapy recommendation for the patient.
The table below summarizes the NCCN recommended NSCLC cancer therapy guideline based on the detection of eleven types of genetic mutations associated with NSCLC tested by Genecast Lung:
Genecast Lung has the following advantages:
Efficient: Genecast Lung provides parallel detection of multiple gene sites, which saves testing time and sample consumption.
Comprehensive: Genecast Lung provides comprehensive gene mutation detection of hotspots and rare and unknown variable loci to determine a targeted therapy result.
Evidence-based: Genecast Lung strictly follows NCCN guidelines to provide a professional and personalized targeted therapy treatment plan.